Collaboration Between 60 Degrees Pharmaceuticals and Tulane University
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW), a forward-thinking pharmaceutical firm, has embarked on an important collaboration with Tulane University. This partnership is aimed at investigating the efficacy of tafenoquine against tick-borne pathogens, specifically Borrelia, the bacteria responsible for Lyme disease, and Bartonella.
Understanding the Challenge of Tick-Borne Diseases
The pathogens Borrelia and Bartonella, alongside another pathogen known as Babesia, are often referred to as the “3Bs” in the Lyme disease community. These organisms are the most frequently encountered in individuals suffering from tick-borne diseases. The complexity of these infections presents a significant health challenge.
Lyme Disease and Its Implications
Acute Lyme disease, or Borreliosis, is caused primarily by Borrelia spp. infections. A prominent concern is the condition known as post-treatment Lyme disease (PTLD), where recovery is believed to be complicated by the persistent presence of low levels of Babesia and Bartonella infections. These pathogens can cause overlapping symptoms, further burdening patients’ recovery.
Significance of the Tafenoquine Study
CEO Geoff Dow expressed the objective of this study: to deepen the understanding of these rapidly spreading diseases and respond to an urgent need for effective treatments. The ongoing trials of tafenoquine in addressing babesiosis are encouraging, and this research in partnership with Tulane aims to clarify its potential role in treating co-infections.
Tafenoquine: A Potential Solution
Tafenoquine is recognized as an 8-aminoquinoline antimalarial drug that has received approval in the U.S. for malaria prophylaxis under the brand name ARAKODA®. After undergoing extensive safety trials spanning up to a year, tafenoquine stands out for its long terminal half-life of approximately 16 days, which allows for less frequent dosing.
Considerations and Challenges
While tafenoquine has shown promise, it is crucial to note that it is not currently approved for the treatment or prevention of Borrelia or Bartonella, nor babesiosis. As research progresses, understanding its dynamics in treating co-infections could be vital for patients afflicted with these diseases.
About ARAKODA®
ARAKODA® was initially discovered by the Walter Reed Army Institute of Research and gained FDA approval for malaria prophylaxis in 2018. Its availability as a prescription-only drug ensures that patients at risk for malaria can effectively safeguard their health while traveling to endemic areas.
Important Safety Information
Although tafenoquine offers significant advantages, particularly in terms of dosing frequency, it is not suitable for everyone. The drug comes with a spectrum of contraindications and potential adverse effects, including hemolytic anemia, particularly in patients with G6PD deficiency. It's mandatory to conduct G6PD testing prior to prescribing ARAKODA® to avoid serious health complications.
Further Information on Safety and Efficacy
The potential adverse reactions associated with tafenoquine include headache, dizziness, and gastrointestinal issues among others. Moreover, women who are pregnant or breastfeeding a G6PD-deficient infant are advised to exercise caution. Reviewing the complete prescribing information is essential for healthcare providers to ensure safe administration.
About 60 Degrees Pharmaceuticals
Founded in 2010, 60 Degrees Pharmaceuticals, Inc. is dedicated to developing innovative medicines aimed at treating infectious diseases that significantly impact public health. The company achieved a significant milestone with the FDA approval of ARAKODA® for malaria prevention and actively collaborates with leading research institutions across the globe to bolster its research endeavors.
Company Mission and Vision
The mission of 60 Degrees Pharmaceuticals reflects a unified commitment to combat infectious diseases with effective and innovative treatments. Supported by various investors, including significant backing from the U.S. Department of Defense, the company's ambitious goals are geared towards transforming healthcare outcomes for those impacted by infectious diseases.
Frequently Asked Questions
What is the purpose of the research agreement with Tulane University?
The research agreement focuses on evaluating tafenoquine against Borrelia and Bartonella in cell cultures, aiming to enhance understanding and treatment of these diseases.
What is Tafenoquine primarily used for?
Tafenoquine is primarily approved for malaria prophylaxis under the brand name ARAKODA® and is being explored for its potential against other infectious diseases.
What are the risks associated with Tafenoquine?
Potential risks include hemolytic anemia, especially in individuals with G6PD deficiency, along with other common side effects such as headache and dizziness.
How does Tafenoquine help with co-infections?
Research is ongoing to assess tafenoquine’s effectiveness in treating co-infections like those caused by Babesia and Bartonella, which complicate Lyme disease recovery.
What is the company vision of 60 Degrees Pharmaceuticals?
60 Degrees Pharmaceuticals aims to provide innovative treatments for infectious diseases while collaborating with research institutions and leveraging advanced medical insights.
